AlloStem Cell Therapy Shows 80% Efficacy in One-Year Type 2 Diabetes Trial
Key Insights
Creative Medical Technology's CELZ-201 demonstrated significant reduction in insulin dependency and stable HbA1c levels in late-stage Type 2 diabetes (search) patients over one year of treatment.
The pilot study of 20 patients showed no serious adverse effects, validating the safety profile of the universal donor cell therapy using the same infusion procedure as their FDA-cleared Type 1 diabetes (search) trial.
With 38 million Americans diagnosed with diabetes and 96 million classified as prediabetic, this breakthrough treatment could offer new hope for the 90-95% affected by Type 2 diabetes (search).
Creative Medical Technology Holdings (search) has achieved a significant breakthrough in diabetes treatment with its universal donor cell therapy, AlloStem (CELZ-201), demonstrating remarkable efficacy in a one-year pilot study for late-stage Type 2 diabetes (search) patients.
Clinical Trial Results and Safety Profile
The pilot study enrolled 20 participants, equally divided between a treatment group receiving CELZ-201 and a control group undergoing optimized medical therapy. The results revealed an impressive 80% overall efficacy rate in reducing insulin dependency and stabilizing hemoglobin A1c levels among treated patients. Notably, no serious adverse effects were reported throughout the one-year follow-up period.
The administration protocol utilized the same infusion procedure currently employed in the company's FDA-cleared Type 1 diabetes (search) clinical trial, demonstrating the versatility and reliability of the delivery method.
Treatment Innovation and Market Impact
CELZ-201 represents a significant advancement as an off-the-shelf, ready-to-use universal cell line. This allogenic approach, using donor cells, offers potential advantages over autologous therapies, particularly for patients who may not be suitable candidates for treatments using their own cells.
Timothy Warbington, President and CEO of Creative Medical Technology, emphasized the significance of these results: "The positive one-year data from the study represents a significant milestone in our mission to revolutionize diabetes treatment and help a wide variety of patients who potentially may not benefit from autologous therapies."
Disease Burden and Therapeutic Need
The development comes at a crucial time in diabetes care. Type 2 diabetes (search) affects approximately 90-95% of the 38 million Americans diagnosed with diabetes, ranking as the eighth leading cause of death in the United States. More concerning is that over 96 million adults are classified as prediabetic, with more than 80% unaware of their condition.
Strategic Development Pipeline
Based on these promising results, Creative Medical Technology is advancing the development of AlloStem for late-stage Type 2 diabetes (search) treatment. The company maintains a diversified portfolio, including:
- CELZ-201 for early-stage Type 1 diabetes
- CELZ-101 for brittle Type 1 diabetes
- CELZ-201 for late-stage Type 2 diabetes
This comprehensive approach positions the company to address multiple aspects of diabetes care, potentially transforming treatment options for millions of patients worldwide.